CINOBAC
LOE ApproachingNDAORALCAPSULE
Approved
Jun 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CINOBAC is an oral small-molecule antibiotic capsule approved by Eli Lilly in 1980. The specific indication and mechanism of action are not documented in available data. This is a mature legacy product with limited contemporary clinical development.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating potential team downsizing or transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CINOBAC has zero linked job postings, reflecting its mature lifecycle and approaching loss of exclusivity. Career opportunities on this product are limited and focused on legacy management rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on CINOBAC at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.